Price Is GSK’s Weapon Ahead Of Tanzeum Launch
Executive Summary
GlaxoSmithKline has priced its once-weekly GLP-1 agonist Tanzeum 64% below the high dose of Novo Nordisk’s market-leading, once-daily Victoza – a sign of the uphill commercial battle it faces against an entrenched rival.
You may also be interested in...
AstraZeneca Hopes Bydureon Pen Will Rewrite GLP-1 Story
FDA approved an easier-to-use pen version of Bydureon for the treatment of type 2 diabetes, but AstraZeneca will need to move quickly and effectively with the launch if it is to establish the brand before other long-acting GLP-1’s enter the market.
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.